Antitumor immunity is mainly mediated by CD8+ T cells that specifically recognize antigenic peptides presented by the major histocompatibility complex (MHC, in vertebrates) or class I human leukocyte antigens (HLA-I, in humans) and are activated to kill tumor cells [2]. This evidence concerns the gene CD8A and neoplasm.